pretty hard to find a comparative when no one else is focused on IIH apart from IXC. So only company in the market attacking this disease.
I assume with the target audience being 1.6 bill growing 3.4% annually isnt the same market as say cancer but still with no known competitors a successful phase 2 trial, cashed up heading into phase 3, approval from EMA (60% target audience being close to 1 billion) I cant see why this is so out of whack with its current valuation. The only thing holding it back is the uncertainty from the FDA, but as many posters have stated, focus on the EMA and stuff the FDA as majority of the market is there anyway.
I guess one day hopefully the market wakes up and this is trading well above $3. Until then its a waiting game like all stocks, waiting for the right news to gain traction/interest
Thanks for the response, hopefully see you as a holder one day. Cheers
- Forums
- ASX - By Stock
- IXC
- Ann: Invex Granted Key European Patent for Exenatide
Ann: Invex Granted Key European Patent for Exenatide, page-72
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.463M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 74259 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.8¢ | 5755 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 74259 | 0.083 |
1 | 125000 | 0.082 |
1 | 84879 | 0.076 |
1 | 6693 | 0.075 |
1 | 500000 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.088 | 5755 | 1 |
0.095 | 100000 | 1 |
0.100 | 2750 | 1 |
0.150 | 713 | 1 |
0.000 | 0 | 0 |
Last trade - 10.04am 16/10/2024 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online